UK markets closed

CRISPR Therapeutics AG (CRSP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
53.38+0.39 (+0.73%)
As of 12:10PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 4.50B
Enterprise value 3.04B
Trailing P/E 124.34
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)11.35
Price/book (mrq)2.39
Enterprise value/revenue 8.22
Enterprise value/EBITDA -15.01

Trading information

Stock price history

Beta (5Y monthly) 1.74
52-week change 37.73%
S&P500 52-week change 323.10%
52-week high 391.10
52-week low 337.55
50-day moving average 369.71
200-day moving average 359.42

Share statistics

Avg vol (3-month) 31.72M
Avg vol (10-day) 31.33M
Shares outstanding 584.88M
Implied shares outstanding 684.88M
Float 878.84M
% held by insiders 11.86%
% held by institutions 178.02%
Shares short (15 Apr 2024) 414.74M
Short ratio (15 Apr 2024) 411.42
Short % of float (15 Apr 2024) 419.70%
Short % of shares outstanding (15 Apr 2024) 417.37%
Shares short (prior month 15 Mar 2024) 414.72M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -41.38%
Operating margin (ttm)34.58%

Management effectiveness

Return on assets (ttm)-6.22%
Return on equity (ttm)-8.17%

Income statement

Revenue (ttm)371.21M
Revenue per share (ttm)4.69
Quarterly revenue growth (yoy)3,353,333.20%
Gross profit (ttm)N/A
EBITDA -202.7M
Net income avi to common (ttm)-153.61M
Diluted EPS (ttm)-1.94
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.69B
Total cash per share (mrq)21.1
Total debt (mrq)238.63M
Total debt/equity (mrq)12.67%
Current ratio (mrq)17.54
Book value per share (mrq)23.52

Cash flow statement

Operating cash flow (ttm)-260.38M
Levered free cash flow (ttm)-238.97M